FreedomWorks Statement in Response to the Trump Administration’s Most Favored Nation Price Control Ruling

WASHINGTON, D.C. — In response to the prescription drug regulations rolled out by the Trump administration today, one of which includes the Most Favored Nation (MFN) proposal, Adam Brandon, FreedomWorks President, commented:

"While we support the Trump administration’s efforts to address pharmacy benefit managers through the Rebate Rule, the Most Favored Nation proposal rolled out today is bad policy, plain and simple. Importing price controls from countries with government-run healthcare will discourage innovation and investment in new pharmaceutical drugs. The MFN rule will also make it so that our country imports the inefficiencies that come with socialized medicine.

“We have been supportive of the administration’s deregulatory agenda, but the Most Favored Nation regulation has serious, lasting implications for our healthcare system. The Trump administration would be wise to think twice about the MFN proposal and the adverse effects it will surely have on patients in need of reliable, quick, and proficient care.”